Given that Ron and Met are related and that these receptors have been reported to interact, targeting both Ron and Met may provide an amplified therapeutic effect for prostate cancer patients by reducing tumor blood flow and nutrients to the tumor proper leading to tumor cell death and prolonged patient survival [37, 38]. This evidence concerns the gene MST1R and neoplasm.